Stem-cell funding still mired in courts
By Steve Johnson,
San Jose Mercury News
| 11. 30. 2005
JUDGE RULES SUITS ON PROPOSITION 71 CAN GO TO TRIAL
By Steve Johnson
Mercury News
A judge Tuesday denied a motion to dismiss two lawsuits challenging the legality of California's year-old $3 billion stem-cell institute, making it likely public funding for the institute will continue to be blocked well into next year.
Alameda County Superior Court Judge Bonnie Sabraw also denied motions by the plaintiffs, who had asked her to declare the stem-cell program unconstitutional.
Sabraw ordered the parties back to court Tuesday to set a trial date, noting that she planned to ``proceed to trial promptly.'' Both sides in the case said it's possible a trial might not begin until spring. Whoever loses at that point is expected to file an appeal, dragging the case out even longer.
Even so, Robert Klein, who chairs the California Institute for Regenerative Medicine, said he was happy with the judge's ruling because it found no immediate reason to declare the stem-cell program unconstitutional.
``We would have loved to have a home run,'' by having the suits dismissed, Klein said. ``But boy, this...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
